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FAMILIAL amyloid polyneuropathy (FAP) is the mostcommon form of herederitary amyloidosis. Initial clin-
ical manifestation is a sensoriomotor polyneuropathy start-
ing in the lower limbs and later affecting the upper extrem-
ities. The autonomic nervous system is involved (orthostatic
hypotension and impotence). Severe constipation (often the
first gastrointestinal symptom) is relieved with time by
bouts of diarrhea that subsequently become continuous.
Cardiac arrhytmias are common. Some patients develop
renal failure because of accumulation of amyloid in the
kidneys together with bladder denervation.1
FAP is characterized by systemic deposition of amyloid.
Amyloid fibrils are composed of variant transthyretin in
which a single amino acid substitution (TTRMet30 in FAP
type 1) results in the aggregation and insolubility of the
protein with deposition in extracellular spaces. More than
95% of TTR is produced in the liver.2 Apart from the
production of the variant transthyretin, FAP livers are
functionally and anatomically normal. The course of the
disease is progressive leading to death within 14 years of the
onset of symptoms. Liver transplantation is the only effec-
tive therapy.3
FAP presents from the third to sixth decade, which
suggests that it can take this long for sufficient amyloid to be
deposited in the tissues. Elderly asymptomatic TTRMet30
homozygotes have been reported.4 Among the heterozy-
gotes, penetrance and rate of disease progression vary
substantially.5
Portugal has several hundreds of FAP type 1 patients for
whom the sole hope of stopping the progression of the
disease is liver transplantation. The severe shortage of
cadaveric donor organs led us6 to consider the use of the
liver removed from these subjects in patients awaiting liver
transplantation. The lean body habitus and the absence of
portal hypertension anticipate an easy hepatectomy. A
young stable donor and the possible short cold ischemic
time should allow excellent conditions for the recipient. The
persistent synthesis of the anomalous TTR by the donated
organ creates the potential for development of neuropathy.
METHODS
From October 1992 to December 31, 1999, 93 cases of FAP were
transplanted at Coimbra University Hospital. Twenty-three pa-
tients donated the liver, and four livers removed at other Institu-
tions were accepted for such an operation. In the same time
interval, we transplanted 110 patients older than 12, not affected by
FAP, and not involved in sequential liver transplantation.
The livers removed from FAP patients were offered to recipients
in desperate condition older than 50. Later on, younger patients
were also considered as potential recipients if the success of the
transplantation could be jeopardized by their clinical condition. In
recent times, any patient with cirrhosis older than 50 was asked
permission for sequential liver transplantation. In all, 25 patients
acted as recipients in the sequential procedure.
Facing an appropriate clinical picture the diagnosis of type 1
FAP was formulated by identification of circulating TTRMet30.
The neurologic deficit of these patients was quantified.7 These
patients were extensively studied before the transplant to exclude
the presence of liver disease other than the metabolic disturbance.
When indicated, the native hepatectomy in the FAP patient
implied technical specificities necessary for the donation. The
suprahepatic inferior vena cava was dissected into the intrapericar-
dial portion with division of the phrenic veins and division of the
diaphragmatic fibrotic ring to ensure sufficient length for both the
implantation of the cadaveric graft and use of the liver as a domino
graft. The hepatic artery was divided at the level of the gastrodu-
odenal artery and the portal vein was divided within 1 cm of the
bifurcation.
Both FAP donors and recipients gave informed written consent
after receiving extensive counseling and information about techni-
cal aspects of the surgery and the potential risk to the recipient of
developing FAP. The possibility of retransplantation was offered,
should FAP develop in the absence of tumor recurrence. The
Ethics Committee at Coimbra University Hospital approved the
procedure.
RESULTS
The 27 FAP patients that donated their livers were 35.6 6
7.2 years old (range 26 to 54). The neurologic disability
scored 30.7 6 11.7% (range 8 to 65). The symptoms caused
4.4 6 1.6 years before transplantation (range 1 to 7). The
BMI was 21.8 6 3.9 kg/m2 (range 14.7 to 29.5).
The cold ischemic time (CIT) was 588.4 6 156.7 minutes
(range 320 to 913 minutes, CIT . 720 minutes in 5 patients
or 23.8%). Arterial hepatic thrombosis was detected in one
case. A biliary leak presented in another patient. Other
major complications were acute renal insufficiency and
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splenic flexure necrosis. Four out the 23 donors operated in
our hospital were retransplanted for PNF, (n 5 2); hepatic
artery thrombosis, or de novo hepatitis C (retransplanted at
14 months).
Three patients died (13%). One patient died after de
novo C virus infection and retransplantation. Another died
suddenly at home 18 months after transplantation (type 2
Mobitz AV block was known). One patient died after a
sudden cardiac arrest at the end of transplantation (a
pacemaker had been introduced immediately before the
operation). Actuarial survival for this cohort was 95.6% at
30 days, 95.4% at 6 months, and 95.0% at 1 year.
CIT for the 70 FAP patients (similar age, neurologic,
score and BMI) not involved in the sequential procedure
was 495 6 141.1.7 minutes (CIT . 720 minutes, 3.0%).
Hepatic artery thrombosis was detected in 5.7%, PNF in
1.4%. Eleven percent were retransplanted. Actuarial sur-
vival was 100% at day 30, 89.5% at 6 months, and 81.9% at
1 year (significantly only for CIT . 720 minutes).
Twenty-five patients received 27 livers removed from
FAP patients. Liver cirrhosis was known in 16 cases, and
metastatic disease in two cases. Other diagnosis were
present in 7 cases (hemangioendothelioma in two cases,
relapse of hepatocellular carcinoma, hepatocholangiocarci-
noma, acute Budd-Chiari syndrome, acute hepatic failure,
hepatocellular carcinoma in normal liver). Hepatocellular
carcinoma was suspected or known in 11 cases (actually
present in 9).
These patients were 48.8 6 9.1 years old (range 28 to 60).
We transplanted four cases younger than 40 (28 years old,
Budd-Chiari, third transplant; 29 years old, hemangioendo-
thelioma; 33 years old, hepatocholangiocarcinoma; 34 years
old, acute hepatic failure, third transplant). Seven more
cases were younger than 50 (40 years old, HBV 1 HVC 1
hepatocellular carcinoma 1 hepatopulmonary syndrome;
44 years old, hepatocellular carcinoma in normal liver; 44
years old, acute hepatic failure; 44 years old, HBV 1
hepatocellular carcinoma; 44 years old, alcoholic cirrhosis;
47 years old, Wilson disease, hepatocellular carcinoma; and
48 years old, neuroendocrine metastasis).
CIT was 457 6 198 minutes (range 135 to 795 minutes).
CIT was less than 300 minutes in seven cases (25.9%). CIT
was over 720 minutes in four patients (14.8%). Arterial
hepatic thrombosis was detected in three cases (15.7%).
Biliary stenosis developed in two cases. A biliary leak was
detected in one patient. The sequential procedure was the
first transplant in 20 cases. Two patients were retrans-
planted.
Twelve patients died. Death was ascribed to infections in
five patients, tumoral relapse in four cases, renal failure,
cererovascular accident, and multiorgan failure. Actuarial
survival for this cohort was 88.0% at day 30, 62.5% at 6
months, and 50.0% at 1 year.
For comparison, in the 110 patients older than 12, not
affected by FAP, and not involved in sequential liver
transplantation operated in the same time interval in our
center, the retransplantation rate was 11.8% (P 5 NS). The
actuarial survival of these group was 84.3% at day 30, 74.4%
at 6 months, and 72.1% at 1 year (significant difference at 1
year).
The recipients were strictly followed to ascertain the
emergence of a polyneuropathy. One case was transplanted
more than 5 years ago, after being diagnosed an hepatocel-
lular carcinoma superimposed on a C cirrhosis. No tumoral
recurrence occurred. He has no neurologic symptoms.
Electromyography of lower limbs is normal. A skin biopsy
(17.02.99) was negative for amyloid.
CONCLUSIONS
With the remarkable exception of producing an anomalous
protein, the liver in patients afflicted by FAP functions well.
With this premise in mind, our group introduced sequential
liver transplantation in 95 patients whereby the liver re-
moved from a patient suffering from FAP is transferred to
another patient. In the meantime, the FAP donor receives
a cadaveric organ.
Mean CIT for cadaveric livers implanted in donors
involved is not different from that observed for livers
transplanted in non donors (588.4 6 156.7 vs 495.2 6 141.1
minutes). Ischemic times greater than 720 minutes are more
frequent in donors (23.8% vs 3.5%) but this difference is
not to be ascribed to the procedure. We observed an
identical prevalence of PNF (8.7% vs 1.4%) or hepatic
artery thrombosis (4.3% vs 5.7%) in both groups. The
hepatectomy on the donor requires technical specificities
not necessary for the normal transplantation. The results of
this series clearly demonstrate that the modifications do not
increase the number of major complications in the patients
that donated their livers, neither increase the frequency of
retransplantation (17.4% vs 11.4%). It is also clear that the
sequential procedure do not compromise the survival of
FAP donors (at 1 year, 76.9% vs 80.7%) or jeopardize the
survival of any individual case.
The actuarial survival of the recipients of FAP livers (at
12 months, 54.1%) is clearly inferior to that observed by our
group for individuals older than 12, without FAP, and not
involved in sequential liver transplantation (at 12 months,
72.1%). The low actuarial survival of this cohort should be
ascribed to the extreme condition of most of the involved
cases. Only 8 (57.1%) out of 14 patients harbouring a tumor
are currently alive. Only 5 (45.4%) out of 11 patients
younger than 50 survived the procedure.
With only one recipient alive more than 5 years after a
sequential liver transplantation, it is probably too early to
ascertain the emergence of the neuropathy in the receptors.
It should be stressed that, in this particular cirrhotic patient,
neurologic symptoms are not present, electromyographic
studies are normal, and skin biopsies do not reveal amyloid
deposition.
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